George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
just played it thanks to desemax's link and sadoldgit mention of 7 mins in at 8.20 tim says about the sdc1801 and sdc1802 compounds but think he also lets slip our compounds
The world’s most innovative treatments for COVID-19 will soon be fast-tracked through the UK’s clinical trial system, as the government announces funding for the most promising treatments.
Bring it all on now we must be in with a chance to really take these things to the conclusion we all need GL DYOR
Desemax. Good for posting the presentation from 2020. 7 mins in gives the advantage of TYk2 Jak1 over competitors
Regards.
SDC-1801 – Autoimmune diseases & Covid-19
• Good efficacy in RA and Psoriasis disease models
• Initial toxicology studies completed
• Aiming to complete tox studies and file an exploratory CTA in H2 2021*
• Projected Phase 1 start early 2022*
• Manufacturing route completed
Last line says it all!
In line with our business model, we continue to engage with potential partners with a view to securing commercial licences when they reach late preclinical or early clinical stages.
Taken from the final results RNS June 2019.
Today’s slides say they are seeking commercial licenses from early-mid clinical stage.
That’s a good advancement and they must be confident.
Love peace and harmony.
Spot on Ahfam
Slide 9 is an absolute belter re AGILE entry
- Clinical trial data shows reduced mortality and time to recovery for hospitalised Covid-19
patients
- Encouraging results with SDC-1801 in initial cellular studies
- SDC-1801 reduces the levels of cytokines associated with ARDS in human lung cells infected with SARs-CoV-2
- Experimental phases to complete by end of June and data analysis to complete shortly thereafter
Strap in all!!
Join the dots c..wombles-
Significant clear opportunities available to Sareum
• No marketed products with selectivity for TYK2 – important for differentiation
• Oral twice-daily dosing in mice, potential for once-daily dosing in humans
• Favourable selectivity profile vs JAK2 and JAK3 kinases (cf tofacitinib, baricitinib)
We are good for AGILE, and could be on the list for Boris's pill for Autumn, Oh many happy returns chaps.
Maybe someone more ITK could look at the BioTrinity presentation from April 2020 with similar (some amended) slides, and come up with an updated summary?
link to 2020 slides....... https://vimeo.com/reecemedia/review/410074815/6d403ad260
Validation after more validation-
• Encouraging results with SDC-1801 in initial cellular studies co-funded by UKRI
• SDC-1801 reduces the levels of cytokines associated with ARDS in human lung cells infected with SARs-CoV-2
• Experimental phases to complete by end of June and data analysis to complete shortly thereafter.
Pairo-Castineira et al. Nature 2021 591, 92–98 Huang et al Lancet 2020; 395:497-506
Berg et al Eur Respir J 2017; 50:1601953 Eli Lilly & Co press release 14 Sept 2020
What what, Sly, Velot, Ttrime other c..wombles-
We're going to go gangbusters, 10-30 bagger in my opinion. Many happy returns chaps.
250m market cap, very clever- just putting it out there for the institutions.
Also from slides
JAK2 and JAK3 inhibition associated with the FDA “black box” warnings for serious infections, lymphoma and thrombosis issued to JAK1/JAK3 inhibitor Xeljanz (tofacitinib) and JAK1/JAK2 inhibitor Olumiant (baricitinib)
SDC-1801 and SDC-1802
• Potent & selective inhibitors of TYK2 and JAK1 kinases
• Oral twice-daily dosing in mice, potential for once-daily dosing in humans
• Favourable selectivity profile vs JAK2 and JAK3 kinases (cf tofacitinib, baricitinib)
• Potential to treat the “cytokine storm” immune system over-reaction that can be fatal in Covid-19 patients
Thanks for that the real deal sounds like its a work in progress now I understand the Tweet
From the slides I read this bit TYK2/JAK1 and Covid-19 Clinical trials of JAK-family inhibitors tofacitinib (Pfizer) and baricitinib (Lilly) in Covid-19 patients are in progress or planned
DYOR but the presentation made sense and more news to follow
http://www.sareum.com/files/9716/2435/3004/TimMitchell-Sareum-BioTrinity-June-2021.pdf
On a different page - http://www.sareum.com/news/presentations/
They have at least made a press release on the website but when will the slides be posted? Dated 21st June says today anyone?
http://www.sareum.com/news/press-releases-and-news/2021/sareum-present-biotrinity-2021-conference/